v3.26.1
Segment Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2026
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Information              
Number of reportable segment | segment           1  
Revenue   $ 1,000       $ 1,000 $ 10,000
Research and development expenses   62,913   $ 43,027   123,352 77,942
General and administrative   15,746   12,136   32,657 24,551
Stock-based compensation   8,619   6,045   17,814 11,431
Net loss $ (111,500) (111,456) $ (80,987) (52,223) $ (33,573) (192,443) (85,796)
Zenas BioPharma (HK) Limited              
Segment Information              
Revenue   1,000   0   1,000 10,000
Single Reportable Segment              
Segment Information              
Revenue   1,000       1,000 10,000
General and administrative   10,988   8,204   21,800 16,814
Acquired in-process research and development   30,000       30,000  
Stock-based compensation   8,619   6,045   17,814 11,431
Other segment items   3,797   (2,940)   7,434 (6,697)
Net loss   $ (111,456)   $ (52,223)   $ (192,443) $ (85,796)
Other segment items, description   Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions   Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions   Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior note as well as realized and unrealized gains and losses on foreign currency transactions
Single Reportable Segment | Obexelimab              
Segment Information              
Research and development expenses   $ 29,394   $ 29,894   $ 61,154 $ 53,254
Single Reportable Segment | Orelabrutinib              
Segment Information              
Research and development expenses   11,206       21,307  
Single Reportable Segment | Other programs (ZB002, ZB004, ZB014, ZB021 & ZB022)              
Segment Information              
Research and development expenses   1,458   400   2,026 736
Single Reportable Segment | Partnered regional programs (ZB001 & ZB005)              
Segment Information              
Research and development expenses   (24)   (137)   (24) (37)
Single Reportable Segment | Unallocated              
Segment Information              
Research and development expenses   $ 17,018   $ 10,757   $ 31,932 $ 20,295